2 March 2012
RIGHTMOVE PLC
DIRECTOR/PDMR SHAREHOLDING
Rightmove plc (the "Company"), has received the following notifications today
from Ed Williams, Managing Director, Nick McKittrick, Chief Operating Officer &
Finance Director and Peter Brooks-Johnson, Managing Director, Rightmove.co.uk:
Ed Williams has confirmed that he has today been awarded Nil cost deferred
shares over 20,183 ordinary shares of 1p each, following achievement of the
2011 bonus targets. The deferred shares are exercisable for 12 months from 2
March 2014. Ed Williams has also been awarded Nil cost performance shares over
39,303 ordinary shares of 1p each. The performance shares are exercisable the
day immediately following the date of the Announcement of the results of the
Company for the 2014 financial year and for a period of two years thereafter.
Following this transaction, the beneficial shareholding of Ed Williams is
1,072,578 ordinary shares representing 0.99% of the ordinary shares in issue
(excluding shares held in treasury). Ed Williams also holds executive and
Sharesave options over 1,894,345 ordinary shares, deferred share awards over
88,587 ordinary shares and 88,592 performance shares.
Nick McKittrick has confirmed that he has today been awarded Nil cost deferred
shares over 20,183 ordinary shares of 1p each following achievement of the 2011
bonus targets. The deferred shares are exercisable for 12 months from 2 March
2014. Nick McKittrick has also been awarded Nil cost performance shares over
39,303 ordinary shares of 1p each. The performance shares are exercisable the
day immediately following the date of the Announcement of the results of the
Company for the 2014 financial year and for a period of two years thereafter.
Following this transaction, the beneficial shareholding of Nick McKittrick is
129,000 ordinary shares representing 0.12% of the ordinary shares in issue
(excluding shares held in treasury). Nick McKittrick also holds executive and
Sharesave options over 1,077,055 ordinary shares, deferred share awards over
80,746 ordinary shares and 88,592 performance shares.
Peter Brooks-Johnson has confirmed that he has today been awarded Nil cost
deferred shares over 14,114 ordinary shares of 1p each following achievement of
the 2011 bonus targets. The deferred shares are exercisable for 12 months from
2 March 2014. Peter Brooks-Johnson has also been awarded Nil Cost performance
shares over 25,935 ordinary shares of 1p each. The performance shares are
exercisable the day immediately following the date of the Announcement of the
results of the Company for the 2014 financial year and for a period of two
years thereafter.
Following this transaction, the beneficial shareholding of Peter Brooks-Johnson
is 4,543 ordinary shares representing 0.0042% of the ordinary shares in issue
(excluding shares held in treasury). Peter Brooks-Johnson also holds executive
and Sharesave options over 271,413 ordinary shares, deferred share awards over
67,328 ordinary shares and 49,632 performance shares.
All the above share awards were made following a meeting of the Remuneration
Committee on 2 March 2012.
This announcement is made under the UKLA's Disclosure and Transparency Rule
3.1.4R.
Ends
Name and contact number for queries:
Liz Taylor 0207 087 0700
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.